EMEA-003047-PIP01-21
Key facts
| Active substance |
B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated covalently to the dibenzocyclooctyne noncleavable linker maytansinoid warhead (BMS-986352)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0420/2021
|
| PIP number |
EMEA-003047-PIP01-21
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of mature B cell neoplasms
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb International Corporation
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|